CHAPTERS
- 0:00 – 4:20
Intro, Premium Channel, and Research Funding Model
Huberman introduces the AMA format, explains the purpose of the premium channel, and outlines how subscription revenue—matched by the Tiny Foundation—supports human-based research on mental, physical, and performance health. He clarifies pricing options and reassures listeners that the main Monday podcast remains free and unchanged.
- •Huberman Lab Podcast discusses science and science-based tools for daily life.
- •Premium channel was created to support the free podcast and fund human research.
- •Tiny Foundation matches every dollar allocated to research from premium revenue.
- •Subscription options: monthly, annual, and lifetime models at hubermanlab.com/premium.
- •Non-subscribers hear the first ~20 minutes of AMAs before the paywall.
- 4:20 – 7:10
What Is Kratom? Origins, Forms, and Basic Effects
Huberman introduces kratom, detailing its origin from Mitragyna speciosa in Indonesia and traditional use via chewing leaves for mild stimulation. He explains that modern preparations concentrate alkaloids into powders and capsules, producing low-dose stimulant effects and higher-dose opioid-like analgesia and sedation.
- •Kratom comes from the Mitragyna speciosa tree, native to Indonesia.
- •Traditionally used by chewing leaves, now often consumed as capsules or powder.
- •Low doses: mild stimulant, slight euphoria for many users.
- •Higher doses: analgesic (painkilling) and sedative effects emerge.
- •Kratom functions pharmacologically as an opioid in the body.
- 7:10 – 10:40
Opioid Crisis Context and Kratom’s Controversial Role
He situates kratom within the broader opioid crisis, characterized by over-prescription and widespread addiction to morphine, oxycodone, and similar drugs. While noting that some individuals claim kratom helped them taper off prescription opioids, he underscores that kratom itself can be addictive and disruptive to multiple life domains.
- •Opioid crisis involves over-consumption and addiction to prescription opioids like morphine and oxycodone.
- •Addiction is defined as continuing use despite negative consequences and as a progressive narrowing of things that provide pleasure.
- •Kratom is also an opioid, though with lower potency than many prescriptions.
- •Some people report using kratom successfully to wean off stronger opioids.
- •Others report severe addiction to kratom itself, including rehab and cross-addiction.
- 10:40 – 15:00
Dueling Camps: Kratom Horror Stories vs. Harm-Reduction Narratives
Huberman describes polarized feedback he received about kratom: one group warns of intense addiction and withdrawal, while another touts kratom as a lifesaving tool for opioid tapering when used at low doses. He relays medical professionals’ nuanced view that kratom may be acceptable only if it’s part of a tightly controlled, temporary step-down from stronger opioids—never a wellness supplement.
- •One vocal camp: kratom led to addiction, withdrawal, rehab, and additional substance problems.
- •Another camp: low-dose kratom as a tool to taper off morphine or hydrocodone.
- •Clinicians Huberman trusts say: if you can avoid kratom, you should.
- •Kratom should not be seen as ‘good for you’ or a general health supplement.
- •If used clinically, it must be part of a clear plan to lower dose and fully stop opioids.
- 15:00 – 18:30
Individual Vulnerability, Addiction Risk, and the “Never Try It” Argument
He drives home the principle that you cannot be addicted to something you never take and stresses large individual differences in opioid responsiveness. A sizable minority feel especially strong euphoria and reinforcement from opioids or alcohol, placing them at high risk for escalating use and addiction—those individuals, especially, should avoid first contact with kratom.
- •Huberman cites colleague Dr. Rob Malenka: no consumption, no addiction.
- •Addiction risk is strongly shaped by brain chemistry and individual variability.
- •Estimated 10–40% of people have particularly strong positive responses to opioids.
- •Parallel: 8–10% of people show elevated dopamine responses to alcohol and are at high risk for alcohol use disorder.
- •Similar logic applied to cannabis: some users deny addiction but resist short abstinence tests, revealing dependence.
- 18:30 – 21:30
Dosing Realities, Product Variability, and Supplement Market Problems
Huberman cautions against simplistic dose guidelines like ‘1–6 grams is safe,’ noting that kratom products vary greatly in alkaloid composition and potency. Because different alkaloids hit opioid receptors differently, gram-for-gram comparisons across brands are misleading, and some users escalate doses and switch products to chase stronger opioid effects.
- •Kratom is sold as an over-the-counter supplement, with no prescription required in the U.S. at present.
- •Different products have different concentrations of key plant alkaloids.
- •One gram of one brand may not equal one gram of another in effect.
- •Certain alkaloid profiles bind the mu‑opioid receptor more strongly.
- •Some users escalate dose and select more potent preparations, approaching effects closer to prescription opioids.
- 21:30 – 25:30
How Opioids and Kratom Work: Endogenous Systems and Receptors
He provides a concise tutorial on the endogenous opioid system, explaining how the body naturally releases opioids during prolonged effort (e.g., runner’s high) to create mild euphoria and pain relief. Kratom, morphine, and hydrocodone hijack this system by binding mu‑opioid (and to a lesser degree kappa) receptors in the brainstem and elsewhere, indirectly activating dopamine and serotonin circuits and driving reinforcement.
- •Endogenous opioids are naturally produced and bind opioid receptors in the brain and body.
- •Runner’s high is an example of natural opioid release causing mild euphoria and analgesia.
- •Kratom, morphine, and hydrocodone all bind the mu‑opioid receptor; kratom also binds some kappa receptors.
- •Blocking mu‑opioid receptors abolishes kratom’s typical stimulant, euphoric, and analgesic effects.
- •Claims that kratom is non-addictive because it doesn’t activate dopamine directly are false; it indirectly activates reinforcement circuitry including dopamine and serotonin.
- 25:30 – 28:10
Challenging “Less Bad” Logic and Emphasizing Risk-Benefit Thinking
Huberman critiques the argument that a drug is acceptable simply because it is ‘less bad’ than another, using cannabis vs. alcohol as a parallel example. He argues that rational evaluation should focus on specific benefits and risks of each substance for particular individuals, not on relative moral rankings between drugs.
- •Common argument: ‘Kratom isn’t as bad as morphine, therefore it’s acceptable’ is logically weak.
- •Similar argument appears in cannabis debates: ‘Cannabis isn’t as bad as alcohol, therefore it’s good.’
- •Each substance must be evaluated on its own profile of risks and benefits.
- •High-THC cannabis is risky for young people with predisposition to psychosis.
- •The same nuanced, evidence-based standard should apply to kratom.
- 28:10 – 31:50
Respiratory Suppression, Physiological Sigh, and Overdose Risk
Drawing on work by Dr. Jack Feldman, Huberman explains that many opioid deaths result from suppressed respiration during sleep due to opioid action on brainstem circuits that generate physiological sighs. While kratom at low-to-moderate doses is not clearly linked to respiratory suppression alone, higher doses and combinations with other depressants can impair breathing and have been implicated in some deaths.
- •Opioids like morphine and hydrocodone suppress respiration via brainstem circuits that control physiological sighs.
- •Physiological sigh is an automatic breathing pattern that helps reinflate lungs and regulate CO₂/O₂.
- •Respiratory failure during sleep is a major mechanism of opioid-related death.
- •Kratom alone at recommended doses appears less likely to suppress respiration, but evidence is limited.
- •Co-use with other opioids or alcohol, or high-dose kratom, can increase risk of respiratory suppression and possible death.
- 31:50 – 34:20
Bottom Line on Kratom: Strong Warning and Limited Use-Case
Huberman concludes that kratom is not a benign herb but a lower-potency opioid with real addiction and overdose risks. He advises people who have never used kratom to avoid it altogether and urges current users—especially those increasing doses or seeking more potent products—to recognize the trap of substituting one opioid dependence for another.
- •Kratom’s addictive potential is well documented, though stronger in some individuals.
- •It can serve as a narrow harm-reduction tool for tapering off more potent opioids, but only under a plan to fully discontinue.
- •Some users who never took prescription opioids have nonetheless become addicted to kratom alone.
- •Potency of kratom is roughly about one-sixth that of hydrocodone, but users can escalate intake.
- •Clear advice: if you’ve never used kratom, don’t start; if you do use it, be extremely cautious and aware of escalation and co-use risks.
- 34:20
Closing: Premium AMA Access and Research Support
He wraps up by reminding listeners that full AMA episodes, transcripts, and exclusive tools are available through the premium channel. Revenues, matched by the Tiny Foundation, fund human-based research on protocols for mental, physical, and performance health that will be shared across all Huberman Lab platforms.
- •Full AMAs and transcripts are available via the premium subscription.
- •Premium funds support both the free podcast and human research studies.
- •Research output will be shared broadly, not only behind the paywall.
- •Subscription cost and match program by the Tiny Foundation are reiterated.
- •Listeners are invited to join at hubermanlab.com/premium to ask questions and support research.
